39719-87-4

Basic information

• Product Name: N-[4-[[(5-methyl-1,3,4-thiadiazol-2-yl)amino]sulphonyl]phenyl]acetamide
• Synonyms: N-[4-[[(5-methyl-1,3,4-thiadiazol-2-yl)amino]sulphonyl]phenyl]acetamide;N-(5-Methyl-1,3,4-thiadiazole-2-yl)-4-(acetylamino)benzenesulfonamide;N-[4-[[(5-Methyl-1,3,4-thiadiazol-2-yl)amino]sulfonyl]phenyl]acetamide
• CAS NO: 39719-87-4
• Molecular Formula: C₁₁H₁₂N₄O₃S₂
• Molecular Weight: 312.36798
• EINECS: 254-606-7
• Mol File: 39719-87-4.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• Density: 1.4583 (rough estimate)
• Refractive Index: 1.6270 (estimate)
• Water Solubility: 0.41g/L(37 oC)
• CAS DataBase Reference: N-[4-[[(5-methyl-1,3,4-thiadiazol-2-yl)amino]sulphonyl]phenyl]acetamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-[4-[[(5-methyl-1,3,4-thiadiazol-2-yl)amino]sulphonyl]phenyl]acetamide(39719-87-4)
• EPA Substance Registry System: N-[4-[[(5-methyl-1,3,4-thiadiazol-2-yl)amino]sulphonyl]phenyl]acetamide(39719-87-4)

Safety Data

• Hazardous Substances Data: 39719-87-4(Hazardous Substances Data)

Usage

InChI:InChI=1/C11H12N4O3S2/c1-7(16)12-9-3-5-10(6-4-9)20(17,18)15-11-14-13-8(2)19-11/h3-6H,1-2H3,(H,12,16)(H,14,15)

Upstream product

• 108-33-8 5-methyl-1,3,4-thiadiazol-2-amine 
• 121-60-8 p-acetylaminobenzenesulfonyl chloride 
• 144-82-1 sulfamethizole 
• 75-36-5 acetyl chloride 
• 98-74-8 4-Nitrobenzenesulfonyl chloride 
• 349621-24-5 N-(5-methyl-1,3,4-thiadiazol-2-yl)-4-nitrobenzenesulfonamide 

Downstream Products

• 144-82-1 sulfamethizole 
• 1191951-65-1 N-(4-(N-(5-methyl-1,3,4-thiadiazol-2-yl)sulfamoyl)phenyl)decanamide 

Relevant articles and documents

MODULATORS OF IMMUNOINHIBITORY RECEPTOR PD-1, AND METHODS OF USE THEREOF

Disclosed are an assay to identify modulators of the PD-1 :PD-L pathway and PD-1 :PD-L pathway modulators, e.g., compounds and pharmaceutical compositions thereof. Methods for treating diseases influenced by modulation of the PD-1 :PD-L pathway such as, for example, autoimmune diseases, inflammatory disorders, allergies, transplant rejection, cancer, immune deficiency, and other immune system-related disorders, are also disclosed.

SMALL MOLECULE INHIBITORS OF THE PLECKSTRIN HOMOLOGY DOMAIN AND METHODS FOR USING SAME

Pleckstrin homology domain binding compounds, pharmaceutical compositions including such compounds, and methods for their use are described herein.